Lonza CEO sees good times ahead for biologics

The views of Markus Gemuend, CEO of Lonza, on biologics are presented. Lonza, the industry leader in biologics for pharmaceuticals, has 345,000 liters of capacity for microbial biologics and 17,400 liters for mammalian cell production. According to him biotechnology is the main field for growth and technology differentiation for fine chemicals industry. In the year 2004, capacity for biologics and protein manufacturing is 413,000 liter, and is estimated that a further 989,000 liters will need to be added by the year 2005.